Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 421 to 430 of 1090 total matches.
Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
in patients with advanced liver disease taking
the combination.
DRUG INTERACTIONS — Lumacaftor is a strong ...
The FDA has approved a fixed-dose combination
of lumacaftor and ivacaftor (Orkambi – Vertex) for
oral treatment of cystic fibrosis (CF) in patients
≥12 years old who are homozygous for the F508del
mutation. About 50% of patients in the US with
CF are homozygous for the F508del (also called
Phe508del) mutation. This is the first approved
indication for lumacaftor; ivacaftor is available
alone as Kalydeco for treatment of CF in patients
≥2 years old with other mutations. Orkambi is the
first drug to be approved in the US for treatment of
patients with the F508del...
Trovafloxacin
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
four weeks.
DRUG INTERACTIONS — Concomitant use of aluminum- and magnesium-containing antacids, iron ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
, and
prolongation of the QT interval. Severe, sometimes
fatal, pneumonitis has been reported.
DRUG INTERACTIONS ...
Ceritinib (Zykadia – Novartis), an oral tyrosine
kinase inhibitor, has received accelerated approval
from the FDA for treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic
non-small cell lung cancer (NSCLC) who have
progressed on or are intolerant to crizotinib (Xalkori).
It is the second tyrosine kinase inhibitor to be approved
for ALK-positive metastatic NSCLC; crizotinib was the
first. Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma.
In Brief: Natalizumab (Tysabri) Withdrawn
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
Letter
®
On Drugs and Therapeutics
Volume 47 (Issue 1204)
March 14, 2005
www.medicalletter.org ...
The February 14th issue of The Medical Letter reviewed natalizumab (Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease...
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
and conjunctivitis
have been reported. Asymptomatic increases in liver
transaminases can occur.
DRUG INTERACTIONS ...
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
Benzhydrocodone/Acetaminophen (Apadaz) for Pain
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
of
hydrocodone bitartrate/acetaminophen (Norco, and generics).
▶ Adverse effects and drug interactions ...
The FDA has approved Apadaz (KemPharm), a short-acting,
fixed-dose combination of benzhydrocodone
and acetaminophen, for short-term management
(≤14 days) of acute pain severe enough to require an
opioid and for which alternative treatment options
are inadequate. Benzhydrocodone is a prodrug of
hydrocodone. Fixed-dose combinations of short-acting
hydrocodone and acetaminophen or ibuprofen
have been available for years and are the most abused
opioid products in the US. Apadaz was developed
under the presumption that inclusion of the inactive
prodrug would reduce the potential for...
Tirzepatide (Zepbound) for Chronic Weight Management
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
, and
diabetic retinopathy complications can occur.
Drug Interactions: Tirzepatide delays gastric emptying ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in 2022, has now been approved as Zepbound (Lilly)
for chronic weight management in adults who have
a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least
one weight-related comorbidity. The injectable
GLP-1 receptor agonists liraglutide (Saxenda) and
semaglutide (Wegovy) are approved for chronic
weight management in patients ≥12 years...
Med Lett Drugs Ther. 2023 Dec 25;65(1692):205-7 doi:10.58347/tml.2023.1692c | Show Introduction Hide Introduction
Voriconazole
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002 (Issue 1135)
(Issue W1135A) July 22, 2002
DRUG INTERACTIONS — Drugs that induce CYP2C9, 2C19 or 3A4, such as rifampin ...
Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp.
Naltrexone (Vivitrol) - A Once Monthly Injection for Alcoholism
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
. Psychopharmacology 2002;
159:351.
10. BJ Mason et al. A pharmacokinetic and pharmacodynamic
drug interaction study ...
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone (Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to maintain abstinence from alcohol. Naltrexone inhibits the rewarding effects of alcohol. Oral naltrexone (Revia, and others) has been approved for treatment of alcohol dependence since 1994, but poor adherence has limited its effectiveness. In the new extended-release (XR) formulation, naltrexone is encapsulated in polylactide-co-glycolide microspheres (similar to absorbable suture material)...
Panitumumab (Vectibix) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Apr 23, 2007 (Issue 1259)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has progressed despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved for metastatic colorectal cancer; cetuximab (Erbitux), a human-murine chimeric IgG1 monoclonal antibody, was approved in 2004.